

AMDL Contact:

Kristine Szarkowitz Director-Investor Relations kszarkowitz@amdl.com (206) 310-5323

AMDL INC. CHAIRMAN & CEO ANNOUNCES EXPERT OPINION ON CHINA'S ECONOMIC FORECAST

January 27, 2009 – (www.amdl.com) China continues to show significant potential to impact global markets according to AMDL, Inc. (Amex Alternext US: ADL-News) Chairman and CEO Mr. Douglas MacLellan. The Company today announced the release of an internal economic forecast research report indicating China as having the #1 highest GDP growth rate in the world, eclipsing every other international market.

Mr. MacLellan has been working in China since 1983 and is a recognized authority on joint venture and wholly foreign owned enterprise (WFOE) structuring. He is a senior international business executive, economist, venture capitalist and merchant banker. MacLellan has been a catalyst for the development and financing of global businesses in the United States and throughout the world in countries that include: Bulgaria, Cambodia, Canada, Chile, China, Hungary, India, Korea, Madagascar and Russia over the past 16 years. Throughout his professional career, as a senior international business executive and or as a member of the board of directors of numerous companies, he has provided management, advice and counsel on strategic planning, operational activities, corporate finance, economic policy, asset allocation and mergers &acquisitions. He has helped raise over US\$715 million for development stage, start-up and mid-cap companies. MacLellan holds extensive experience developing businesses in China, including a thorough understanding of the regulatory framework and how to work with local authorities. He has substantial contacts in the Chinese government and business communities.

To view Mr. MacLellan's report on the growing Chinese market visit www.amdl.com.

About AMDL:

Headquartered in Tustin, CA with operations in Shenzhen, Jiangxi, and Jilin, China, AMDL, Inc., along with its subsidiary Jade Pharmaceutical Inc. (JPI), is a vertically integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products. The company employs over 490 people in the U.S. and China.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.